Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.

Pharmacogenomics - 1 Dec 2019

Yuliwulandari Rika, Prayuni Kinasih, Susilowati Retno Wilujeng, M Sofro Abdul Salam, Tokunaga Katsushi, Shin Jae-Gook

Abstract excerpt

Aim: We investigated the contribution of NAT2 variants and acetylator status to anti-tuberculosis drug-induced liver injury (AT-DILI) severity. Materials & methods: 100 patients with clinically severe AT-DILI and 210 non-AT-DILI controls were subjected to NAT2 genotyping by direct DNA sequencing. Results: NAT2 slow acetylator was significantly associated with AT-DILI risk (p = 2.7 × 10-7; odds ratio [95% CI]...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Chemical and Drug Induced Liver Injury

Share to Indonesia

Share to Isoniazid

Share to Severity of Illness Index

Share to Tuberculosis

Source

Identifiers

PMID: 31699005
DOI: 10.2217/pgs-2019-0131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.PMID 31699005Read ↗

NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Semantic proximity Read ↗

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.Semantic proximity Read ↗

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.Semantic proximity Read ↗

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.Semantic proximity Read ↗

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients.Semantic proximity Read ↗

Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia.Semantic proximity Read ↗

Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Semantic proximity Read ↗

Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patientsSemantic proximity Read ↗

Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.